Mainz Biomed (MYNZ) Short Interest Ratio & Short Volume

Short interest is the volume of Mainz Biomed shares that have been sold short but have not yet been covered or closed out. As of February 28th, traders have sold 79,700 shares of MYNZ short. 3.78% of Mainz Biomed's shares are currently sold short. Learn More on Mainz Biomed's current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 3.78% of Mainz Biomed's floating shares are currently sold short.

Mainz Biomed saw a decrease in short interest during the month of February. As of February 28th, there was short interest totaling 79,700 shares, a decrease of 21.6% from the previous total of 101,700 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Mainz Biomed currently has issued a total of 2,001,000 shares. Some of Mainz Biomed's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Mainz Biomed currently has a public float of 2,110,000 shares.

3.78% of Mainz Biomed's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Mainz Biomed: Tenaya Therapeutics, Inc. (11.32%), Forte Biosciences, Inc. (0.24%), FibroGen, Inc. (5.37%), 23andMe Holding Co. (10.71%), Precision BioSciences, Inc. (20.13%), Reviva Pharmaceuticals Holdings, Inc. (15.56%), Xilio Therapeutics, Inc. (4.74%), Prelude Therapeutics Incorporated (7.94%), Barinthus Biotherapeutics plc (0.03%), bluebird bio, Inc. (20.64%),

As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($23.74 billion), iShares 20+ Year Treasury Bond ETF ($10.75 billion), MicroStrategy Incorporated ($6.56 billion), Apollo Global Management, Inc. ($5.40 billion), Charter Communications, Inc. ($4.57 billion), AppLovin Co. ($4.45 billion), Capital One Financial Co. ($4.33 billion), Super Micro Computer, Inc. ($4.23 billion), Schlumberger Limited ($3.22 billion), and Royal Caribbean Cruises Ltd. ($3.06 billion). View all of the most shorted stocks.

Short selling MYNZ is an investing strategy that aims to generate trading profit from Mainz Biomed as its price is falling. MYNZ shares are trading up $0.23 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Mainz Biomed occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of MYNZ, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including MYNZ, twice per month. The most recent reporting period available is February, 28 2025.